These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: CT-guided percutaneous core needle biopsy in oncology outpatients: sensitivity, specificity, complications.
    Author: Steil S, Zerwas S, Moos G, Bittinger F, Hansen T, Mergenthaler U, Weide R.
    Journal: Onkologie; 2009 May; 32(5):254-8. PubMed ID: 19420971.
    Abstract:
    BACKGROUND: Inpatient CT-guided core needle biopsies are an integral diagnostic method to obtain a histology from lesions of unknown dignity in oncology. The purpose of this study was to evaluate feasibility, sensitivity, specificity, and complication rate of diagnostic CT-guided percutaneous core needle biopsies in oncology outpatients. PATIENTS AND METHODS: We retrospectively analyzed data of all oncology outpatients who received CT-guided core needle biopsies between August 2001 and March 2005. RESULTS: 432 outpatients received 465 CT-guided core needle biopsies using a 14-, 16-, or 18-gauge coaxial cutting needle. 174 patients (37%) were biopsied for intra-abdominal lesions, 130 (28%) for intrathoracic lesions, 55 (12%) for bone lesions, 40 (9%) for peripheral tumors, 36 (8%) for peripheral lymph nodes, and 30 (7%) for central lymph nodes. 249 (53%) biopsies were performed in local anesthesia, 216 (47%) in general anesthesia. Sensitivity was 94%, specificity 92%, and effective accuracy 92%. Complications occurred after 23 biopsies (4.9%). A pneumothorax occurred after 17 thorax biopsies (13%). 7 patients (1.5%) had to be hospitalized after the biopsy. No patient died due to the procedure. CONCLUSION: CT-guided core needle biopsies are feasible and safe in oncology outpatients. The technique shows a high diagnostic sensitivity and specificity with a low complication rate in routine care.
    [Abstract] [Full Text] [Related] [New Search]